Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years old~2. Patients having PCI with stenting 24 hours prior randomization, meeting the following criteria :~   * Acute coronary syndrome (unstable angina or myocardial infarction)~  * TIMI risk score\>2~3. Platelet reactivity in PRU ≥235 24 hours post-PCI~4. Age≥75 years and/or weight\<60 Kg~4. Informed consent obtained in writing~Exclusion Criteria:~* A history of bleeding diathesis~* Chronic oral anticoagulation treatment~* Contraindications to antiplatelet therapy~* Known platelet function disorders~* PCI or coronary artery bypass surgery \< 3 months~* Unsuccessful PCI (residual stenosis \> 30% or flow \< Thrombolysis in myocardial infarction flow 3)~* Planned staged PCI in the next 30 days~* Hemodynamic instability~* hemodialysis~* Creatinine clearance \<25 ml/min~* inability to give informed consent~* High likelihood of being unavailable for the Day 30~* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.~* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on longterm antiplatelet therapy.~* Any previous history of ischemic stroke, transient ischemic attack, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).~* Thrombocytopenia (\<100.000 / μL) at randomization~* Anaemia (Hct \<30%) at randomization~* Polycythaemia (Hct \> 52%) at randomization~* Periprocedural IIb/IIIa inhibitor administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 150mg per day for 15 days
- Prasugrel (Type: EXPERIMENTAL): Prasugrel 5mg for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).